2 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Ranjana Advani: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma Magrolimab, Pembrolizumab, PET/CT - Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Terminated | Ranjana Advani | 8 | 2022-06-21 | 2026-06-30 |
| International Extranodal NK/T-cell Lymphoma Project Extranodal NK/T-cell Lymphoma, Nasal Type | Completed | Samsung Medical Center | 770 | 2013-01-01 | 2017-04-11 | |
| Rituximab in Treating Patients With Hodgkin's Lymphoma Rituximab - Lymphoma, Hodgkin Lymphoma (Category) | Phase 2 | Completed | Ranjana Advani | 39 | 1999-01-01 | 2017-04-20 |
Hodgkin Disease (2) · Lymphoma (1) · Lymphoma, Extranodal NK-T-Cell (1)
Biosimilar Pharmaceuticals (1) · Rituximab (1) · magrolimab (1) · pembrolizumab (1)
United States (2) · South Korea (1)
Ranjana H Advani, MD (2) · Richard T Hoppe, MD (1) · Won Seog Kim, MD, PhD (1)